ClinOne offers a single platform that connects, informs, and empowers patients, care partners, and trial sites, supporting trial awareness, consent management, and patient experience/retention. The platform is underpinned by comprehensive data-insights tools and standards-based interoperability to simplify processes. Its solutions are used by more than 80 sponsors, CROs, and site networks across 60 countries and serve therapeutic areas including Oncology, Rare Disease, Pediatrics, the Elderly, and CNS. ClinOne states its solutions are proven to reduce risk and simplify processes for sponsors and sites. The company intends to use newly raised funds to expand operations and its business reach. ClinOne is based in Needham, MA. ClinOne offers a platform for trial and consent management, patient engagement, comprehensive data-insights tools, and interoperability to connect patients, caregivers, and sites in clinical trials. The platform is used by more than 80 sponsors, CROs, and site networks across 60 countries. Its product aims to reduce risk and simplify complex processes across therapeutic areas including oncology, rare disease, pediatrics, the elderly, and CNS. Led by CEO Andrea Valente, ClinOne emphasizes patient and site empowerment through its suite of tools. The company recently completed a $3M Series A to support growth. It intends to use the funds to accelerate platform development and broaden its customer reach. ClinOne operates the ClinOne and ClinTrialConnect platforms to enable pharmaceutical sponsors, research sites and participants to perform and automate recruitment, study execution, compliance and patient retention from any location worldwide. Its modular product suite includes patient recruitment, remote consent (eConsent), patient-reported outcomes and surveys (ePRO), dosing management and remote vital-sign data collection, and it integrates with home healthcare visits and telemedicine video visits. ClinOne conducts clinical trials in 55 countries across 43 languages. The company added the CU Healthcare Innovation Fund as lead investor in a Series-A financing with a first closing of $3.6 million. Management said the funding will be used to expand the product suite and sales efforts to meet high demand. The announcement also referenced a partnership with portfolio company BioIntelliSense to enable more robust remote patient monitoring in clinical trial management.

Total raised

$9M

Funding rounds

3

Latest round

Series A

Latest activity

Nov 2023